A 10-year survey of clinically significant blood culture isolates and antibiotic susceptibilities from adult patients with hematological diseases at a major Swedish hospital.
In patients treated with cytotoxic drugs granulocytopenia and septicemia are commonly seen. In this 10-year survey 324 blood culture isolates from 184 patients with hematological diseases and septicemia were studied. The distribution of microbiological diagnoses in patients with hematological diseases as well as acute leukemia 1980-1986 was significantly different (p less than 0.01) from an unselected blood culture material from the same period. The differences are mainly seen between Enterobacteriaceae other than Escherichia coli, Pseudomonas aeruginosa and staphylococci. The microbiological spectrum for patients with hematological disease 1987-1989 was also significantly different (p less than 0.05) from the spectrum of the same group of patients 1980-1986 due to higher frequencies of coagulase-negative staphylococci and alpha-streptococci and lower frequency of E. coli in the latter period. 40% of the isolates were gram-positive cocci during the first period and increased to 50% during the second period. The susceptibility testing indicates that trimethoprim/sulfonamide is not as good a choice as ciprofloxacin or norfloxacin for oral antibiotic prophylaxis. For intravenous therapy imipenem/cilastatin or the combinations of an aminoglycoside/piperacillin or aminoglycoside/third generation cephalosporin have advantages over aminoglycoside/trimethoprim/sulfa in combination. However, addition of isoxazolylpenicillin or vancomycin now seems necessary to cover the increasing part of gram-positive bacteria causing septicemia in patients with hematological disease.
Fredlund
H
H
Department of Clinical Microbiology, Orebro Medical Center Hospital, Sweden.
Björeman
M
M
Kjellander
J
J
Sjöberg
L
L
Bjorne
L
L
Ohlin
A L
AL
D042462:4-Quinolones; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000890:Anti-Infective Agents / Q000627:therapeutic use; D001420:Bacteria, Aerobic / Q000302:isolation & purification; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D005260:Female; D006402:Hematologic Diseases / Q000150:complications / Q000188:drug therapy / Q000382:microbiology*; D006801:Humans; D007938:Leukemia / Q000150:complications; D015470:Leukemia, Myeloid, Acute / Q000150:complications; D008223:Lymphoma / Q000150:complications; D008297:Male; D008826:Microbial Sensitivity Tests; D012189:Retrospective Studies; D018805:Sepsis / Q000188:drug therapy / Q000382:microbiology*; D013548:Sweden; D013997:Time Factors
D042462:4-Quinolones; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents